Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of SIAC vs Mix30 in Type 2 Diabetes
NCT00842361Phase 2Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2009
- Primary completion
- Jun 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of insulin degludec + insulin aspart in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Novo Nordisk. Primary endpoints: Rate of Major and Minor Hypoglycaemic Episodes at 6 weeks and Rate of Nocturnal Major and Minor Hypoglycaemic Episodes at 6 weeks. Started Jan 2009; status: completed.
02
Drugs
insulin degludec + insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00842361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00842361.